VEEV

Veeva delivered a strong Q3 FY2027 with revenue of $811 million and non-GAAP operating income of $365 million, both exceeding guidance and driving a full-year raise. The headline story, however, is a nuanced one: while the company secured its 14th top-20 biopharma commitment to Vault CRM (including Eli Lilly), it also disclosed that six of the top 20 have opted for alternative solutions, primarily Salesforce. Management characterized this as customer-specific dynamics rather than a systemic competitive loss, emphasizing that CRM represents only 20% of total revenue (down from 25% two years ago) and that the company remains on track for 2030 targets. The real growth engines are elsewhere: Crossix delivered outperformance, R&D showed broad strength, and services momentum, particularly business consulting, is accelerating. Veeva AI emerged as a central strategic pillar, with management outlining an aggressive roadmap to deploy agentic solutions across all product areas by end-of-2026, starting with commercial and safety in Q1 2026. The company is positioning itself as an integrated industry cloud for life sciences, combining software, data (Crossix), and consulting capabilities in ways competitors have not attempted. On the margin front, near-term headwinds from Salesforce royalties and AWS hosting costs during CRM migrations will be modest and immaterial, with expansion resuming in the out years. Management noted no material change in pharma end-market demand despite macro uncertainty around tariffs and geopolitical tensions, and signaled confidence in the IQVIA partnership as a long-term commercial tailwind. The quarter validates Veeva's diversified business model: while CRM attrition is real, it is manageable and offset by strength in higher-growth areas like Crossix, quality/manufacturing, and the emerging AI-driven workflow automation opportunity.